NCT Number: NCT06120491
Phase: PHASE3
Trial Summary: The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician’s choice NHA relative to placebo + physician’s choice NHA by assessment of radiographic progression-free sur – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): AstraZeneca
Acronym: EvoPAR-PR01
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician’s Choice New Hormonal Agents
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives